[{"id":"e2ef80d0-17a8-472e-9917-3abc5f89a030","acronym":"","url":"https://clinicaltrials.gov/study/NCT03676959","created_at":"2021-01-18T18:01:58.632Z","updated_at":"2024-07-02T16:36:30.358Z","phase":"Phase 1","brief_title":"A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer","source_id_and_acronym":"NCT03676959","lead_sponsor":"Lee's Pharmaceutical Limited","biomarkers":" PD-L1 • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Shan Ke Yu (socazolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 101","initiation":"Initiation: 08/16/2018","start_date":" 08/16/2018","primary_txt":" Primary completion: 05/15/2022","primary_completion_date":" 05/15/2022","study_txt":" Completion: 10/15/2022","study_completion_date":" 10/15/2022","last_update_posted":"2021-05-13"},{"id":"07b13f6c-153d-4796-a0d9-67d0352358da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03676985","created_at":"2021-01-18T18:01:59.008Z","updated_at":"2025-02-25T16:25:17.229Z","phase":"Phase 1/2","brief_title":"A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma","source_id_and_acronym":"NCT03676985","lead_sponsor":"Lee's Pharmaceutical Limited","biomarkers":" PD-L1 • CD14","pipe":"","alterations":" ","tags":["PD-L1 • CD14"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Shan Ke Yu (socazolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/10/2018","start_date":" 10/10/2018","primary_txt":" Primary completion: 02/14/2020","primary_completion_date":" 02/14/2020","study_txt":" Completion: 06/23/2023","study_completion_date":" 06/23/2023","last_update_posted":"2018-09-26"},{"id":"5afd35a5-c3d5-4fb6-879b-727804b1f1a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03676946","created_at":"2021-01-18T18:01:58.331Z","updated_at":"2024-07-02T16:37:06.568Z","phase":"Phase 1/2","brief_title":"A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma","source_id_and_acronym":"NCT03676946","lead_sponsor":"Lee's Pharmaceutical Limited","biomarkers":" PD-L1 • CD14","pipe":"","alterations":" ","tags":["PD-L1 • CD14"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Shan Ke Yu (socazolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/10/2018","start_date":" 10/10/2018","primary_txt":" Primary completion: 02/14/2020","primary_completion_date":" 02/14/2020","study_txt":" Completion: 06/23/2023","study_completion_date":" 06/23/2023","last_update_posted":"2018-09-26"}]